Changeflow GovPing Healthcare & Life Sciences Glycerol Phenylbutyrate ANDA 220568 Approved fo...
Priority review Rule Added Final

Glycerol Phenylbutyrate ANDA 220568 Approved for Navinta LLC

Favicon for www.accessdata.fda.gov FDA Drugs@FDA - New Applications and Actions
Published
Detected
Email

Summary

FDA approved Abbreviated New Drug Application (ANDA) 220568 for Glycerol Phenylbutyrate 1.1GM/ML oral liquid submitted by Navinta LLC on April 23, 2026. The drug received TE Code AA (therapeutic equivalence to reference listed drug), indicating it meets FDA standards for generic substitution. This approval adds a fifth generic manufacturer for this urea cycle disorder treatment, joining Aurobindo Pharma, MSN, PH Health, and Teva Pharma.

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Drugs@FDA - New Applications and Actions for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 14 changes logged to date.

What changed

FDA granted approval to Navinta LLC for ANDA 220568 covering Glycerol Phenylbutyrate oral liquid at 1.1GM/ML strength. The application received standard review priority with no orphan status designation. The approval grants Prescription marketing status under TE Code AA (therapeutic equivalence), meaning the generic is substitutable for the reference listed drug Ravicti manufactured by Horizon Therapeutics.

Generic drug manufacturers producing or marketing Glycerol Phenylbutyrate formulations should note this additional market entrant. Healthcare providers and pharmacists may consider therapeutic equivalence options when prescribing or dispensing. The approval expands the pool of available generics for this ammonia detoxifying agent used in urea cycle disorder management.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

*Home | *

Abbreviated New Drug Application (ANDA): 220568
Company: NAVINTA LLC
- Email

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription AA No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/23/2026 ORIG-1 Approval STANDARD Label is not available on this site.

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL; 1.1GM/ML
TE Code = AA

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription No AA 220313 AUROBINDO PHARMA
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription No AA 219540 MSN
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription No AA 220568 NAVINTA LLC
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription No AA 205742 PH HEALTH
GLYCEROL PHENYLBUTYRATE GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription No AA 218738 TEVA PHARMS INC
RAVICTI GLYCEROL PHENYLBUTYRATE 1.1GM/ML LIQUID;ORAL Prescription Yes AA 203284 HORIZON THERAP US

Get daily alerts for FDA Drugs@FDA - New Applications and Actions

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Substantive

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Generic drug approval ANDA approval Drug approval
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Healthcare

Get alerts for this source

We'll email you when FDA Drugs@FDA - New Applications and Actions publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!